Over the last few years, the pharmaceutical and biotechnology industries have experienced a reduction in development output, as measured by original new drug applications (NDAs) and biologics license applications (BLAs). Simultaneously, the costs for bringing drug candidates through the development chain have increased, as has the pressure to deliver more value with limited resources. Industry leaders now recognise the necessity of operational efficiency to achieve a substantial competitive advantage.
To successfully stay ahead of these trends, industry leaders recognise the value of an integrated operations and business planning framework. Organisations can use this framework to evaluate their operational readiness and address key business questions. PricewaterhouseCoopers can help clients through the application of process-based, integrated operations and business planning methodologies.